Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 24, Issue 6, 2011, Pages 529-534

  Gaglia, Michael A ^a   Torguson, Rebecca ^a   Pakala, Rajbabu ^a   Xue, Zhenyi ^a   Sardi, Gabriel ^a   Suddath, William O ^a   Kent, Kenneth M ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; CELL ADHESION MOLECULES; CONFIDENCE INTERVALS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 83955161719     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00670.x     Document Type: Article

References (17)

1. Bonello L, Tantry US, Marcucci R, et al,. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
2. Gurbel PA, Antonino MJ, Bliden KP, et al,. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
3. Price MJ, Endemann S, Gollapudi RR, et al,. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. (Pubitemid 351844676)
4. Bonello L, Paganelli F, Arpin-Bornet M, et al,. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636. (Pubitemid 47091403)
5. Cuisset T, Hamilos M, Sarma J, et al,. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008; 101: 1700-1703.
6. Marcucci R, Gori AM, Paniccia R, et al,. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009; 119: 237-242.
7. Breet NJ, van Werkum JW, Bouman HJ, et al,. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-762.
8. Mani H, Luxembourg B, Klaffling C, et al,. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005; 58: 747-750. (Pubitemid 40956832)
9. Linnemann B, Schwonberg J, Mani H, et al,. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-683. (Pubitemid 351404936)
10. Gurbel PA, Bliden KP, Samara W, et al,. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832. (Pubitemid 41579803)
11. Michelson AD,. Methods for the measurement of platelet function. Am J Cardiol 2009; 103 (3 Suppl): 20A-26A.
12. Cattaneo M, Hayward CP, Moffat KA, et al,. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
13. van Werkum JW, van der Stelt CA, Seesing TH, et al,. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4: 2516-2518. (Pubitemid 44575456)
14. von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al,. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
15. Paniccia R, Antonucci E, Gori AM, et al,. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847. (Pubitemid 47288940)
16. Lordkipanidze M, Pharand C, Nguyen TA, et al,. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885.
17. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310. (Pubitemid 16134762)